Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
Share
Why It Matters
Arrowhead found their Alzheimer's medicine reduced a harmful protein by 85%. When a medicine shows it works in early tests, watch if the company stays on track.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.